PSMA total tumor volume outpredicts SUV and PSA for overall survival in large PET registry

Retrospective · J Nucl Med · 2026-11-13. Number 4 in the UrologyWatch Top 5 for November 13, 2026.

Among 13,893 prostate cancer patients in the PROMISE PET Registry split into development (n=9271) and validation (n=4622) cohorts, PSMA total tumor volume predicted overall survival in the validation cohort with a C-index of 0.78 (95% CI, 0.77-0.80), outperforming whole-body SUVmean (0.62; 95% CI, 0.61-0.64) and PSA at PET (0.71; 95% CI, 0.69-0.72), and performing similarly to PSMA total lesion uptake (0.78) and PSA times TTV (0.77).

Why it matters: A straightforward volumetric PSMA PET measurement may offer a more reliable way to stratify overall survival risk than SUV or PSA alone.

Limitation: This was a retrospective multicenter registry analysis, and the validation cohort was drawn from the same registry population rather than an independent external dataset.

Source: J Nucl Med · PubMed 43020616 · DOI 10.2967/jnumed.126.273371

The full November 13, 2026 edition · Today's urology news

Loading today's edition…